Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134366 · ClinicalTrials.gov registry record · Phase 3
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
A Phase 3 study, sponsored by The Cooper Health System.
- Terminated
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
NCT02134366 is a Phase 3 study that was terminated before completion, run by The Cooper Health System. The registered enrollment target is 7 participants.
The verdict
NCT02134366, a Phase 3 study, was terminated before completion, sponsored by The Cooper Health System.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.
Interventions
- DRUG Clonazepam
- DRUG Lorazepam
- DRUG Clobazam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134366
The ClinicalTrials.gov registry entry for NCT02134366 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Clonazepam is the first listed.
NCT02134366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02134366 about?
NCT02134366 is a clinical study titled "Clobazam Use in Epilepsia Partialis Continua - Pilot Study". The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.
What is the current status of trial NCT02134366?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2014-07. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02134366?
The interventions under investigation include: Clonazepam (DRUG), Lorazepam (DRUG), Clobazam (DRUG).
Who is sponsoring clinical trial NCT02134366?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.